What is HC Wainwright’s Forecast for Altimmune Q3 Earnings?

Altimmune, Inc. (NASDAQ:ALT) – Research analysts at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for shares of Altimmune in a note issued to investors on Monday, August 17th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.13) per share for the quarter, up from their prior forecast of ($0.15). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Altimmune’s Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.56) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.16) EPS, Q4 2027 earnings at ($0.17) EPS, FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.63) EPS, FY2029 earnings at ($0.39) EPS and FY2030 earnings at ($0.15) EPS.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 31.41%.

A number of other equities research analysts have also issued reports on the company. Citizens Jmp cut their price target on Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Wall Street Zen upgraded Altimmune from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research note on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Wednesday, June 24th. Finally, Leerink Partners began coverage on Altimmune in a research note on Monday, June 22nd. They set an “outperform” rating and a $10.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Altimmune currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.33.

Altimmune Stock Performance

ALT opened at $2.97 on Wednesday. The company has a market cap of $577.58 million, a price-to-earnings ratio of -3.81 and a beta of 0.27. Altimmune has a 12-month low of $2.56 and a 12-month high of $6.44. The company’s 50 day moving average is $2.91 and its 200 day moving average is $3.34. The company has a current ratio of 26.78, a quick ratio of 26.78 and a debt-to-equity ratio of 0.07.

Institutional Trading of Altimmune

Hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its position in Altimmune by 268.7% during the first quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock valued at $3,221,000 after purchasing an additional 762,223 shares during the period. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Altimmune by 156.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company’s stock worth $1,575,000 after purchasing an additional 316,209 shares during the period. Leonteq Securities AG boosted its holdings in shares of Altimmune by 6,400.0% in the 1st quarter. Leonteq Securities AG now owns 65,000 shares of the company’s stock worth $200,000 after purchasing an additional 64,000 shares during the period. North Star Investment Management Corp. increased its position in shares of Altimmune by 112.5% during the 1st quarter. North Star Investment Management Corp. now owns 17,000 shares of the company’s stock valued at $52,000 after purchasing an additional 9,000 shares during the last quarter. Finally, Wealth Effects LLC increased its position in shares of Altimmune by 18.1% during the 1st quarter. Wealth Effects LLC now owns 131,950 shares of the company’s stock valued at $406,000 after purchasing an additional 20,200 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune News Roundup

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.56 from $0.63 and its FY2027 estimate to a loss of $0.63 from $0.80. The firm also improved estimates for several quarterly periods, including Q3 and Q4 2026 and Q1–Q4 2027. Altimmune analyst estimates
• Positive Sentiment: Longer-term forecasts were also upgraded: FY2028 EPS improved to a loss of $0.63 from $1.02, FY2029 to a loss of $0.39 from $0.55, and FY2030 to a loss of $0.15 from $0.32. These changes suggest the analyst expects Altimmune’s path toward profitability to be better than previously anticipated. Altimmune long-term earnings estimates
• Neutral Sentiment: Despite the upgrades, HC Wainwright still expects Altimmune to remain unprofitable through 2030, with a projected FY2027 loss of $0.63 per share and a FY2026 consensus loss of $0.60. Investors will continue to focus on clinical progress, funding needs and the company’s ability to convert its pipeline into commercial revenue.
• Negative Sentiment: Altimmune remains a loss-making biotechnology company, with a negative PE ratio and substantial negative net margin. The revised forecasts reduce expected losses but do not yet represent projected earnings or confirmed profitability.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.